Cargando…
GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by cognitive decline, brain atrophy due to neuronal and synapse loss, and formation of two pathological lesions: extracellular amyloid plaques, composed largely of amyloid-beta peptide (Aβ), and neurofibrillary tangles...
Autores principales: | Nava-Mesa, Mauricio O., Jiménez-Díaz, Lydia, Yajeya, Javier, Navarro-Lopez, Juan D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070063/ https://www.ncbi.nlm.nih.gov/pubmed/24987334 http://dx.doi.org/10.3389/fncel.2014.00167 |
Ejemplares similares
-
Amyloid-β induces synaptic dysfunction through G protein-gated inwardly rectifying potassium channels in the fimbria-CA3 hippocampal synapse
por: Nava-Mesa, Mauricio O., et al.
Publicado: (2013) -
Implications of GABAergic Neurotransmission in Alzheimer’s Disease
por: Li, Yanfang, et al.
Publicado: (2016) -
The Glutamine Transporter Slc38a1 Regulates GABAergic Neurotransmission and Synaptic Plasticity
por: Qureshi, Tayyaba, et al.
Publicado: (2019) -
Fluorescent Biosensors for Neurotransmission and Neuromodulation: Engineering and Applications
por: Leopold, Anna V., et al.
Publicado: (2019) -
Amyloid Precursor Protein (APP) and GABAergic Neurotransmission
por: Tang, Bor Luen
Publicado: (2019)